Intrinsiqs

Is Kymera Therapeutics, Inc. overvalued?

Kymera Therapeutics, Inc. (KYMR) — key valuation metrics and fundamentals.

No verdict
Price
$111.95
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$9.21B
Dividend yield
0.0%
Return on equity
-21.5%
Sector
Healthcare

See the full interactive analysis →

Fair value compares KYMR's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.